Serum metabolomics of treatment response in myasthenia gravis

OBJECTIVE: High-dose prednisone use, lasting several months or longer, is the primary initial therapy for myasthenia gravis (MG). Upwards of a third of patients do not respond to treatment. Currently no biomarkers can predict clinical responsiveness to corticosteroid treatment. We conducted a discov...

Descripción completa

Detalles Bibliográficos
Autores principales: Sikorski, Patricia, Li, Yaoxiang, Cheema, Mehar, Wolfe, Gil I., Kusner, Linda L., Aban, Inmaculada, Kaminski, Henry J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564178/
https://www.ncbi.nlm.nih.gov/pubmed/37816000
http://dx.doi.org/10.1371/journal.pone.0287654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564178/
https://www.ncbi.nlm.nih.gov/pubmed/37816000
http://dx.doi.org/10.1371/journal.pone.0287654

Ejemplares similares